

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 12, 2013

Sucampo Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-33609

30-0520478

(State or Other Juris-
diction of Incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

4520 East-West Highway, 3rd Floor
Bethesda, Maryland

20814

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (301) 961-3400

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure.

During February 12-14, 2013, Sucampo Pharmaceuticals, Inc. ("Company") will make corporate update presentations at one-on-one meetings with analysts and investors in New York City, NY. On February 12, 2013, the Company will make a corporate update presentation via webcast at an investor conference in New York City, NY at the 15th Annual BIO CEO & Investor Conference. On February 14, 2013, the Company will make a corporate update presentation via webcast at an investor conference in New York City, NY at the Leerink Swann Global Healthcare Conference 2013. All meetings will include modifications to three slides from those slides filed on Form 8K dated January 7, 2013. The additional slides are being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 The modifications of the five slides to the corporate update presentation slides dated February 12, 2013.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SUCAMPO PHARMACEUTICALS, INC.

Date: February 12, 2013

By: /s/ Thomas J. Knapp

Name: Thomas J. Knapp

Title: EVP, Chief Legal Officer and Corporate Secretary

AMITIZA Intellectual Property

- AMITIZA has a robust patent estate
 - Latest patents expire in 2027
- Paragraph IV certification notice letter to Sucampo received on January 2, 2013 regarding ANDA submitted to FDA by Anchen Pharmaceuticals and Par Pharmaceuticals
 - Notice letter alleges AMITIZA's composition, method of use, and/or formulation patents are invalid, unenforceable, and/or will not be infringed by Anchen's manufacture, use or sale of the product described in its ANDA.
- On February 8 Sucampo announced it had filed a patent infringement lawsuit against Anchen and Par Pharmaceuticals
 - Sucampo is joined by Takeda and R-Tech Ueno in the lawsuit

Under Hatch-Waxman Act, patent infringement lawsuit will stay FDA approval of Anchen's ANDA for up to 30 months from receipt of Jan 2 '13 Notice letter

RESCULA US Launch Overview

- sNDA approved December 2012
 - RESCULA may be used as a first-line agent or concomitantly with other topical ophthalmic drug products to lower intraocular pressure
 - RESCULA is a BK (Big Potassium) channel activator, which is different from other intraocular pressure (IOP) lowering agents.
 - RESCULA is believed to reduce elevated IOP by increasing the outflow of aqueous humor through the trabecular meshwork
- RESCULA launch in US Q1 2013
 - 40 specialty reps
 - Product has been shipped to pharmacies and wholesale agreements are in place
 - We will begin filling scripts in late February with WAC price of \$99
 - Heavy sampling to facilitate patient trial

Key Facts

Trading Symbol	SCMP (NASDAQ)
Corporate Headquarters	Bethesda, MD
Stock Price (02-07-2013), 52-Week Range	\$5.22, \$8.50 to \$3.78
Shares Outstanding (9-30-2012)	41.9 M (1 class of common stock)
Daily Volume (90-day average)	105,422
Market Capitalization (02-07-2013)	\$219.1 M
Debt (9-30-12)	\$61.2 M
Cash & Equivalents (9-30-12)	\$82.1 M
Enterprise Value (02-07-2013)	\$198.1 M
YTD Total Revenue (9-30-2012)	\$46.6 M
Full-time Employees (02-08-2013)	123
Fiscal Year Ends	December 31
Accounting Firm	PricewaterhouseCoopers, LLP